Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77


PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients.

Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, Hicks JL, Park BH, Humphreys E, Partin AW, Han M, Netto GJ, Isaacs WB, De Marzo AM.

Clin Cancer Res. 2011 Oct 15;17(20):6563-73. doi: 10.1158/1078-0432.CCR-11-1244.


Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers.

Burdelski C, Kleinhans S, Kluth M, Hube-Magg C, Minner S, Koop C, Graefen M, Heinzer H, Tsourlakis MC, Wilczak W, Marx A, Sauter G, Wittmer C, Huland H, Simon R, Schlomm T, Steurer S.

Int J Cancer. 2016 Mar 1;138(5):1199-206. doi: 10.1002/ijc.29860.


Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer.

Cuzick J, Yang ZH, Fisher G, Tikishvili E, Stone S, Lanchbury JS, Camacho N, Merson S, Brewer D, Cooper CS, Clark J, Berney DM, Møller H, Scardino P, Sangale Z; Transatlantic Prostate Group..

Br J Cancer. 2013 Jun 25;108(12):2582-9. doi: 10.1038/bjc.2013.248.


In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading.

Picanço-Albuquerque CG, Morais CL, Carvalho FL, Peskoe SB, Hicks JL, Ludkovski O, Vidotto T, Fedor H, Humphreys E, Han M, Platz EA, De Marzo AM, Berman DM, Lotan TL, Squire JA.

Virchows Arch. 2016 May;468(5):607-17. doi: 10.1007/s00428-016-1904-2.


A robust immunohistochemical assay for detecting PTEN expression in human tumors.

Sangale Z, Prass C, Carlson A, Tikishvili E, Degrado J, Lanchbury J, Stone S.

Appl Immunohistochem Mol Morphol. 2011 Mar;19(2):173-83. doi: 10.1097/PAI.0b013e3181f1da13.


Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.

Gumuskaya B, Gurel B, Fedor H, Tan HL, Weier CA, Hicks JL, Haffner MC, Lotan TL, De Marzo AM.

Prostate Cancer Prostatic Dis. 2013 Jun;16(2):209-15. doi: 10.1038/pcan.2013.8.


PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer.

Sircar K, Yoshimoto M, Monzon FA, Koumakpayi IH, Katz RL, Khanna A, Alvarez K, Chen G, Darnel AD, Aprikian AG, Saad F, Bismar TA, Squire JA.

J Pathol. 2009 Aug;218(4):505-13. doi: 10.1002/path.2559.


Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer.

Reid AH, Attard G, Brewer D, Miranda S, Riisnaes R, Clark J, Hylands L, Merson S, Vergis R, Jameson C, Høyer S, Sørenson KD, Borre M, Jones C, de Bono JS, Cooper CS.

Mod Pathol. 2012 Jun;25(6):902-10. doi: 10.1038/modpathol.2011.207.


The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.

Grupp K, Boumesli R, Tsourlakis MC, Koop C, Wilczak W, Adam M, Sauter G, Simon R, Izbicki JR, Graefen M, Huland H, Steurer S, Schlomm T, Minner S, Quaas A.

Int J Cancer. 2014 Sep 15;135(6):1399-407. doi: 10.1002/ijc.28778.


PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity.

Choucair K, Ejdelman J, Brimo F, Aprikian A, Chevalier S, Lapointe J.

BMC Cancer. 2012 Nov 22;12:543. doi: 10.1186/1471-2407-12-543.


Determination of Optimum Formalin Fixation Duration for Prostate Needle Biopsies for Immunohistochemistry and Quantum Dot FISH Analysis.

Sathyanarayana UG, Birch C, Nagle RB, Tomlins SA, Palanisamy N, Zhang W, Hubbard A, Brunhoeber P, Wang Y, Tang L.

Appl Immunohistochem Mol Morphol. 2015 May-Jun;23(5):364-73. doi: 10.1097/PAI.0000000000000085.


Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer.

Chaux A, Peskoe SB, Gonzalez-Roibon N, Schultz L, Albadine R, Hicks J, De Marzo AM, Platz EA, Netto GJ.

Mod Pathol. 2012 Nov;25(11):1543-9. doi: 10.1038/modpathol.2012.104.


High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.

Grupp K, Wilking J, Prien K, Hube-Magg C, Sirma H, Simon R, Steurer S, Budäus L, Haese A, Izbicki J, Sauter G, Minner S, Schlomm T, Tsourlakis MC.

Eur J Cancer. 2014 Mar;50(4):852-61. doi: 10.1016/j.ejca.2013.12.003.


Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.

McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR.

Cancer Res. 1999 Sep 1;59(17):4291-6.


Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence.

Grupp K, Kohl S, Sirma H, Simon R, Steurer S, Becker A, Adam M, Izbicki J, Sauter G, Minner S, Schlomm T, Tsourlakis MC.

Mod Pathol. 2013 May;26(5):733-42. doi: 10.1038/modpathol.2012.206.


Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma.

Sakr RA, Barbashina V, Morrogh M, Chandarlapaty S, Andrade VP, Arroyo CD, Olvera N, King TA.

Appl Immunohistochem Mol Morphol. 2010 Jul;18(4):371-4. doi: 10.1097/PAI.0b013e3181d50bd5.


Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.

Krohn A, Diedler T, Burkhardt L, Mayer PS, De Silva C, Meyer-Kornblum M, Kötschau D, Tennstedt P, Huang J, Gerhäuser C, Mader M, Kurtz S, Sirma H, Saad F, Steuber T, Graefen M, Plass C, Sauter G, Simon R, Minner S, Schlomm T.

Am J Pathol. 2012 Aug;181(2):401-12. doi: 10.1016/j.ajpath.2012.04.026.


Optimal protocol for PTEN immunostaining; role of analytical and preanalytical variables in PTEN staining in normal and neoplastic endometrial, breast, and prostatic tissues.

Maiques O, Santacana M, Valls J, Pallares J, Mirantes C, Gatius S, García Dios DA, Amant F, Pedersen HC, Dolcet X, Matias-Guiu X.

Hum Pathol. 2014 Mar;45(3):522-32. doi: 10.1016/j.humpath.2013.10.018.


High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy.

Grupp K, Habermann M, Sirma H, Simon R, Steurer S, Hube-Magg C, Prien K, Burkhardt L, Jedrzejewska K, Salomon G, Heinzer H, Wilczak W, Kluth M, Izbicki JR, Sauter G, Minner S, Schlomm T, Tsourlakis MC.

Mod Pathol. 2014 Jan;27(1):96-106. doi: 10.1038/modpathol.2013.127.


Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies: implications for cancer risk stratification and biomarker sampling.

Shah RB, Bentley J, Jeffery Z, DeMarzo AM.

Hum Pathol. 2015 May;46(5):698-706. doi: 10.1016/j.humpath.2015.01.008.

Items per page

Supplemental Content

Support Center